IS5275A - Meðhöndlun á insúlín viðnámi með vaxtarhormóna seyti - Google Patents

Meðhöndlun á insúlín viðnámi með vaxtarhormóna seyti

Info

Publication number
IS5275A
IS5275A IS5275A IS5275A IS5275A IS 5275 A IS5275 A IS 5275A IS 5275 A IS5275 A IS 5275A IS 5275 A IS5275 A IS 5275A IS 5275 A IS5275 A IS 5275A
Authority
IS
Iceland
Prior art keywords
treatment
growth hormone
insulin resistance
hormone secretion
secretion
Prior art date
Application number
IS5275A
Other languages
English (en)
Icelandic (is)
Inventor
Albert Carpino Philip
Kwok-Fung Chiu Charles
Allen Lefker Bruce
Codetta Pan Lydia
Lee Treadway Judith
Paul Zawistoski Michael
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS5275A publication Critical patent/IS5275A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IS5275A 1997-06-25 1999-11-26 Meðhöndlun á insúlín viðnámi með vaxtarhormóna seyti IS5275A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25
PCT/IB1998/000876 WO1998058949A1 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues

Publications (1)

Publication Number Publication Date
IS5275A true IS5275A (is) 1999-11-26

Family

ID=21967444

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5275A IS5275A (is) 1997-06-25 1999-11-26 Meðhöndlun á insúlín viðnámi með vaxtarhormóna seyti

Country Status (40)

Country Link
US (3) US6448263B1 (cg-RX-API-DMAC7.html)
EP (1) EP1000085B1 (cg-RX-API-DMAC7.html)
JP (2) JP2000514099A (cg-RX-API-DMAC7.html)
KR (1) KR20010014224A (cg-RX-API-DMAC7.html)
CN (2) CN1530107A (cg-RX-API-DMAC7.html)
AP (1) AP1145A (cg-RX-API-DMAC7.html)
AR (1) AR012256A1 (cg-RX-API-DMAC7.html)
AT (1) ATE305477T1 (cg-RX-API-DMAC7.html)
AU (1) AU747510B2 (cg-RX-API-DMAC7.html)
BG (1) BG104008A (cg-RX-API-DMAC7.html)
BR (1) BR9810477A (cg-RX-API-DMAC7.html)
CA (1) CA2294464A1 (cg-RX-API-DMAC7.html)
CO (1) CO4950621A1 (cg-RX-API-DMAC7.html)
DE (1) DE69831745T2 (cg-RX-API-DMAC7.html)
DZ (1) DZ2539A1 (cg-RX-API-DMAC7.html)
EA (1) EA002089B1 (cg-RX-API-DMAC7.html)
EG (1) EG21712A (cg-RX-API-DMAC7.html)
ES (1) ES2248899T3 (cg-RX-API-DMAC7.html)
HN (1) HN1998000088A (cg-RX-API-DMAC7.html)
HR (1) HRP980361A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0001922A3 (cg-RX-API-DMAC7.html)
ID (1) ID24345A (cg-RX-API-DMAC7.html)
IL (7) IL133626A0 (cg-RX-API-DMAC7.html)
IN (1) IN189724B (cg-RX-API-DMAC7.html)
IS (1) IS5275A (cg-RX-API-DMAC7.html)
MA (1) MA24581A1 (cg-RX-API-DMAC7.html)
NO (1) NO996205L (cg-RX-API-DMAC7.html)
NZ (1) NZ500655A (cg-RX-API-DMAC7.html)
OA (1) OA11242A (cg-RX-API-DMAC7.html)
PA (1) PA8452601A1 (cg-RX-API-DMAC7.html)
PE (1) PE105399A1 (cg-RX-API-DMAC7.html)
PL (1) PL337659A1 (cg-RX-API-DMAC7.html)
SK (1) SK175699A3 (cg-RX-API-DMAC7.html)
TN (1) TNSN98113A1 (cg-RX-API-DMAC7.html)
TR (1) TR199903257T2 (cg-RX-API-DMAC7.html)
TW (1) TW553943B (cg-RX-API-DMAC7.html)
UA (1) UA64751C2 (cg-RX-API-DMAC7.html)
WO (1) WO1998058949A1 (cg-RX-API-DMAC7.html)
YU (1) YU70199A (cg-RX-API-DMAC7.html)
ZA (1) ZA985546B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
US6541634B2 (en) * 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
WO2004027064A2 (en) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
PL1828480T3 (pl) * 2004-12-21 2014-10-31 Solenis Tech Cayman Lp Reaktywne żywice kationowe do zastosowania jako czynniki wzmacniające na sucho i na mokro w układach wytwarzania papieru zawierających jony siarczynowe
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EA200901077A1 (ru) 2007-02-09 2010-04-30 Транзим Фарма, Инк. Макроциклические модуляторы грелинового рецептора и их применение
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
RU2403902C1 (ru) * 2009-06-15 2010-11-20 Илья Николаевич Медведев Способ снижения биологического возраста при нарушении толерантности к глюкозе
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
US9499543B2 (en) * 2013-05-28 2016-11-22 Raqualia Pharma Inc. Polymorph forms
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
KR101980180B1 (ko) * 2014-08-05 2019-05-20 라퀄리아 파마 인코포레이티드 그렐린 수용체 작용제로서의 세린 유도체
EP3212648A1 (en) 2014-10-31 2017-09-06 RaQualia Pharma Inc. Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN120265641A (zh) * 2023-04-21 2025-07-04 长春金赛药业有限责任公司 GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632A (zh) * 2024-10-09 2025-01-10 威海中腾医药科技有限公司 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3202660A (en) 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
AU676525B2 (en) 1992-11-06 1997-03-13 Merck & Co., Inc. Substituted dipeptide analogs promote release of growth hormone
WO1994013696A1 (en) 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
CA2175218A1 (en) 1993-11-09 1995-05-18 Gregori J. Morriello Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (en) * 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
EP0869974B1 (en) 1995-12-22 2009-03-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
AU7445498A (en) * 1997-06-25 1999-01-04 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)

Also Published As

Publication number Publication date
HN1998000088A (es) 1999-01-08
EG21712A (en) 2002-02-27
US20030100561A1 (en) 2003-05-29
IN189724B (cg-RX-API-DMAC7.html) 2003-04-19
AP9801267A0 (en) 1998-06-30
IL133626A0 (en) 2001-04-30
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
IL154115A0 (en) 2003-07-31
PE105399A1 (es) 1999-11-04
IL154111A0 (en) 2003-07-31
HUP0001922A3 (en) 2001-02-28
IL156465A (en) 2004-07-25
DZ2539A1 (fr) 2003-02-08
CN1152049C (zh) 2004-06-02
OA11242A (en) 2003-07-23
MA24581A1 (fr) 1998-12-31
PL337659A1 (en) 2000-08-28
SK175699A3 (en) 2001-04-09
ES2248899T3 (es) 2006-03-16
JP3742643B2 (ja) 2006-02-08
IL156465A0 (en) 2004-01-04
US6448263B1 (en) 2002-09-10
PA8452601A1 (es) 2000-05-24
CA2294464A1 (en) 1998-12-30
AP1145A (en) 2003-02-14
WO1998058949A1 (en) 1998-12-30
JP2005097261A (ja) 2005-04-14
BG104008A (en) 2000-07-31
HRP980361A2 (en) 1999-02-28
CN1530107A (zh) 2004-09-22
JP2000514099A (ja) 2000-10-24
US6867202B1 (en) 2005-03-15
EA199901075A1 (ru) 2000-08-28
UA64751C2 (uk) 2004-03-15
NO996205D0 (no) 1999-12-15
KR20010014224A (ko) 2001-02-26
CN1259140A (zh) 2000-07-05
HK1028051A1 (en) 2001-02-02
BR9810477A (pt) 2007-05-22
EP1000085A1 (en) 2000-05-17
AU747510B2 (en) 2002-05-16
AU7445698A (en) 1999-01-04
IL154114A0 (en) 2003-07-31
EA002089B1 (ru) 2001-12-24
NO996205L (no) 1999-12-15
TR199903257T2 (xx) 2000-12-21
CO4950621A1 (es) 2000-09-01
DE69831745D1 (de) 2006-02-09
ID24345A (id) 2000-07-13
ZA985546B (en) 2000-01-10
AR012256A1 (es) 2000-09-27
IL154116A0 (en) 2003-07-31
YU70199A (sh) 2003-01-31
NZ500655A (en) 2002-02-01
DE69831745T2 (de) 2006-08-31
US6630487B2 (en) 2003-10-07
TNSN98113A1 (fr) 2005-03-15
EP1000085B1 (en) 2005-09-28
TW553943B (en) 2003-09-21
ATE305477T1 (de) 2005-10-15

Similar Documents

Publication Publication Date Title
IS5275A (is) Meðhöndlun á insúlín viðnámi með vaxtarhormóna seyti
DE69531573D1 (de) Implantierbare rohrförmige Prothese mit Manschetten
DE69804533D1 (de) Ballonkatheter mit Impeller zur Blutförderung
DE69731979D1 (de) Dialysekatheter mit starren und kollabierbaren lumina
DE69711561D1 (de) Vorgefüllte Spritze
DE69733027D1 (de) Infusionsballonkatheter
DE69504241D1 (de) Vorgefüllte Spritze
NO20001242D0 (no) April - et nytt protein med veksteffekter
DE69618028D1 (de) Medizinische zuleitung mit kompressionslumen
DE69825451D1 (de) Kanüle mit mehreren leitungen
DE69723504D1 (de) Absaugkatheter mit vorgeformter Spitze
DE69727968D1 (de) Ablations-katheter mit mehreren elektroden
DE69726584T2 (de) Selbstzerstörende Spritze
BR9612678A (pt) Seringa descartável
DK0821006T3 (da) Insulinderivater med öget zinkbinding
DE69810382D1 (de) Spritzennadel
NO960485L (no) Selvdestruerende injeksjonsspröyte
ATE305790T1 (de) Behandlung der diabetes mit thiazolidindione, insulin sekretionförderer und biguanide
DE69904407D1 (de) Automatische Insulininjektionsspritze mit Arztmode
DE69318821D1 (de) Katheter zur Versorgung des Penis mit Medikamenten
IL133143A0 (en) Treatment of diabetes with rosiglitazone and insulin
ATE355033T1 (de) Zahnimplantat mit verbesserter stabilität
AU7609298A (en) Treatment of heart failure with growth hormone
SI1007085T1 (en) Use of growth hormone in compositions for treating insulin resistance in the heart
KR950032278U (ko) 인슐린 패치용 피부 처리기